Kite Pharma

12 stories about Kite Pharma
פרופסור זליג אשחר

Scientist Quarrel Over Kite Pharma Sale Royalties to be Settled Out of Court

28.05.18|Zohar Shahar Levy
Israeli immunologist Zelig Eshhar, who holds the patent for Kite Pharma’s anti-cancer technology, has been sued by a former student for infringement of patent rights
חיים לייבוביץ' מנכ"ל בריינסטורם

Israeli ALS Treatment Developer Recruits Kite Pharma's CSO as Board Member

05.02.18|Dror Reich
Nasdaq-listed BrainStorm develops stem cell therapies for degenerative neurological diseases
ראש הממשלה בנימין נתניהו 3.1.17

CTech’s Daily Israeli Tech News Roundup

Israel’s government and tech Industry brace for U.S. tax reform. Activist fund Elliott pushes to overhaul board of Israel's biggest telecom provider
פרופסור זליג אשחר

Scientist’s Ex-Wife Joins Legal Melee Over Kite Pharma Windfall

16.01.18|Zohar Shahar Levy
Zelig Eshhar, the patent holder for Kite Pharma’s anti-cancer technology, is currently being sued by a former student for infringement of patent rights
אריה בלדגרין דוקטור מנכל ו ממייסדי קייט פארמה

CTech’s Daily Israeli Tech News Roundup

Immunologists Exchange Verbal Blows in Legal Fight Over Kite Pharma Windfall. Qatar is buying a lot of weapons to as a leverage against boycott. A $1.43 billion expansion plan announced for Israel’s main airport
פרופסור זליג אשחר

Immunologists Exchange Verbal Blows in Legal Fight Over Kite Pharma Windfall

26.12.17|Zohar Shahar Levy
In August, Gilead Science bought anti-cancer treatment company Kite Pharma for $11.9 billion. Two Israeli scientists involved in the early research that led to the company’s breakthrough are now quarreling over patent royalty payments
מייסד קייט פארמה אריה בלדגרין

Gilead Builds on Kite Pharma Acquisition, Buys Second CAR-T Therapy Company

10.12.17|Lilach Baumer
California-based Cell Design Labs will be acquired in a deal valued at up to $567 million
default image

Generic Focus made Kite Pharma Founder Leave Teva

13.11.17|Dror Reich
Founder of cancer treatment company sold to Gilead Sciences for $12 billion, says Gilead wants “to crack the cancer market"
default image

Kite Pharma’s Cancer Drug Gets Regulatory Nod

19.10.17|Lilach Baumer
The cancer-treatment company, bought by Gilead Science in August for $11.9 billion, will sell one treatment course of the drug for $373,000
מוסף שבועי 14.9.17 פרופ' גידי גרוס

Kite Pharma Sale Triggers Scientist Quarrel

02.10.17|Zohar Shahar Levy
Zelig Eshhar who patented the company’s core technology is now being sued by his former PhD student and current pharma entrepreneur
default image

Meet Kite Pharma's CEO, the Man Bringing Hope to Hodgkin's Lymphoma Patients

30.08.17|Dror Reich
With two exits worth hundreds of millions of dollars to his name even before selling Kite Pharma for $12 billion dollars, just where will Arie Belldegrun aim next?
default image

Gilead To Buy Kite Pharma for $11.9 Billion

29.08.17|Dror Reich
The drug company is looking to diversify into cell therapy following declining hepatitis c drug sales